E-ISSN: 1308-5263
A Promising New Therapy of Oral Ixazomib Without Rituximab for Waldenstrom Macroglobulinemia [Turk J Hematol]
Turk J Hematol. 2021; 38(1): 87-89 | DOI: 10.4274/tjh.galenos.2020.2020.0521  

A Promising New Therapy of Oral Ixazomib Without Rituximab for Waldenstrom Macroglobulinemia

Wanlu Ma1, JiaWei Zhao2, Lu Zhang3
1Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Department of Endocrinology, Beijing, China
2Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Department of Rheumatology, Beijing, China
3Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Department of Hematology, Beijing, China

Keywords: Waldenstrom macroglobulinemia, Rituximabinduced thrombocytopenia, Ixazomib


Waldenström Makroglobulinemisinde Rituksimab İçermeyen Yeni Umut Verici Oral Iksazomib Tedavisi

Wanlu Ma1, JiaWei Zhao2, Lu Zhang3
1Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Department of Endocrinology, Beijing, China
2Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Department of Rheumatology, Beijing, China
3Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Department of Hematology, Beijing, China

Anahtar Kelimeler: Waldenström makroglobülinemisi, Rituksimab ile indüklenen trombositopeni, Iksazomib


Wanlu Ma, JiaWei Zhao, Lu Zhang. A Promising New Therapy of Oral Ixazomib Without Rituximab for Waldenstrom Macroglobulinemia. Turk J Hematol. 2021; 38(1): 87-89

Corresponding Author: Lu Zhang, China


TOOLS
Full Text PDF
Print
Download citation
RIS
EndNote
BibTex
Medlars
Procite
Reference Manager
Share with email
Share
Send email to author

Similar articles
PubMed
Google Scholar


 



Impact Factor (2019) = 1.685